Don’t Let this Opportunity Go Up in Smoke!

Hexo Corp. (TSX:HEXO) remains one of the most misunderstood, yet lucrative long-term opportunities in the cannabis sector.

| More on:
TIMER SAYING TIME FOR ACTION

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Investors that took advantage of the rally that transpired in the new cannabis market before and shortly after legalization last fall are now reflecting on some impressive gains. Hexo (TSX:HEXO) is one such example that deserves a closer look, particularly with regard to several growth opportunities that lie on the horizon for investors.

Let’s take a closer look at those opportunities and what they mean for the longer-term investor.

Hexo is growing

Hexo recently acquired Newstrike Brands, which provided a handsome boost to Hexo’s capacity, as well as finally establishing Hexo as one of the larger cannabis players on the market. This is a significant development because up until that acquisition, Hexo was viewed as more of an acquisition target than a major player to the market despite solidifying a series of key supply and distribution deals across multiple provinces.

Taking into account Hexo’s newest acquisition, the company’s capacity is now set to come in near 150,000 kilograms per year, and production space will see an impressive bump by 470,000 square feet, adding to a series of new production facilities constructed over the past year, including a flagship one-million square foot facility completed at the end of last year. Hexo now has supply agreements across eight provinces, and in the case of Quebec, a multi-year supply agreement with annual upticks in supply.

Perhaps one of the most intriguing developments made by Hexo over the past year was the company’s joint venture to develop a line of cannabis-infused beverages, which is expected to come to fruition later this year. The unit charged with bringing that to market is called Truss, a result of the partnership between Hexo and Molson Coors.

Hexo is clearly looking at establishing a first-to-market advantage on this front, and given the excitement the new product segment is garnering, investors could be handsomely rewarded.

Hexo is more diverse than most realize

In addition to its supply agreements with the provinces and the ongoing developments at Truss, Hexo has several other ongoing initiatives that should be of interest to investors. First, there’s Hexo’s line of Elixir products, which the company forged an agreement to sell in the Liquor Distribution Branch stores in B.C. last year.

Then there’s Hexo’s international venture. The company is currently in the process of establishing a processing, production and distribution centre in Greece, which will in turn cater to the growing medical cannabis market in the E.U. as regulations there continue to ease. Greece legalized cannabis for medicinal use in March of last year, and the European market share for cannabis use is set to hit $110 billion within a decade.

Isn’t Hexo expensive?

Hexo’s stock price has more than doubled since the turn of the year, and while that may trigger some concerns and warnings from some investors, the fact of the matter remains that the cannabis market is still in its infancy at a global level, with Canada serving as ground zero in many ways. Yes, there is a risk, and yes, the stock may appear to be expensive at the moment, but over the course of a longer timeframe, Hexo will only go up.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou owns shares of HEXO. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »